ObsEva (NASDAQ:OBSV) Earns Hold Rating from Analysts at StockNews.com

Posted by on May 2nd, 2025

Investment analysts at StockNews.com started coverage on shares of ObsEva (NASDAQ:OBSV – Get Free Report) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the stock.

ObsEva Price Performance

ObsEva has a fifty-two week low of $0.08 and a fifty-two week high of $2.14. The stock has a market cap of $7.94 million, a price-to-earnings ratio of -0.11 and a beta of 0.68.

ObsEva Company Profile

(Get Free Report)

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Read More

Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.